Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €67.01 EUR
Change Today -1.54 / -2.24%
Volume 956.0
As of 3:11 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€68.09
Previous Close
€68.55
Day High
€68.27
Day Low
€66.74
52 Week High
03/23/15 - €70.86
52 Week Low
05/7/14 - €41.83
Market Cap
74.4B
Average Volume 10 Days
1.1K
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
02/11/15
P/E TM
--
Dividend
€1.91
Dividend Yield
2.33%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Audited Consolidated Cash Flow Results for Year Ended December 31, 2014

Eli Lilly and Company announced audited consolidated cash flow results for year ended December 31, 2014. For the year, the company reported net cash provided by operating activities was $4,367.1 million against $5,735.0 million a year ago. Purchases of property and equipment were $1,162.6 million against $1,012.1 million a year ago.

OncoMed Pharmaceuticals, Inc. and Eli Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) in Lung Cancer

OncoMed Pharmaceuticals, Inc. announced that it has entered into an agreement with Eli Lilly and Company. Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta® (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC). Under the terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial. OncoMed initiated enrollment in the randomized Phase 2 DENALI trial in January 2015 to test the efficacy and safety of demcizumab in combination with Alimta and carboplatin. Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology. The DENALI trial is expected to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.

Eli Lilly & Co. Wins £220.9 Million Multiple Awardees Contract for Supplying Proprietary Pharmaceuticals

Eli Lilly & Co. Ltd. won a £220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €67.01 EUR -1.54

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.29 USD -0.30
AstraZeneca PLC 4,750 GBp -78.50
Bristol-Myers Squibb Co $65.35 USD +1.67
Medtronic PLC $76.49 USD -0.53
Teva Pharmaceutical Industries Ltd $64.91 USD +1.42
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 33.0x
Price/Sales 4.0x
Price/Book 5.1x
Price/Cash Flow 34.2x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.